Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol

A randomized controlled study

Research output: Contribution to journalArticle

229 Citations (Scopus)

Abstract

Objective: To study the efficacy of synthetic 1,25 dihydroxyvitamin D3 (calcitriol) in the treatment of osteoporosis. Design: Two-year, double-blind, randomized clinical trial. Setting: University medical center. Patients: Fifty postmenopausal women with vertebral fractures recruited by referral. Intervention: Calcium intake was adjusted to 25 mmol/d (1000 mg/d) at baseline. Patients were then randomized to treatment with either calcitriol or placebo. During the study, calcium intake was reduced to 15 mmol/d (600 mg/d) and the dose of calcitriol was adjusted to maintain serum calcium <2.74 mmol/L (<11.0 mg/ dL) or urine calcium <9.96 mmol/d (<400 mg/d). Measurements and Main Results: After 2 years, the mean dose of calcitriol in the treated group was 0.62 μg/d. Bone mineral density of the spine increased 1.94% with calcitriol therapy and decreased 3.92% with placebo (P = 0.001). Total body calcium increased 0.21% with calcitriol therapy and decreased 1.85% with placebo (P = 0.004). Patients receiving placebo had significant decreases in spine density (P = 0.0007) and total body calcium (P = 0.0004). There were no differences in vertebral fracture rates between the groups. Renal function studies were not statistically different between the groups after 2 years. The treatment of postmenopausal osteoporotic women with synthetic calcitriol for 2 years was associated with increases in spine density and total body calcium. No adverse effects on renal function were seen after long-term calcitriol therapy.

Original languageEnglish
Pages (from-to)649-655
Number of pages7
JournalAnnals of Internal Medicine
Volume113
Issue number9
StatePublished - Nov 1 1990

Fingerprint

Postmenopausal Osteoporosis
Calcitriol
Calcium
Placebos
Spine
Therapeutics
Kidney
Bone Density
Osteoporosis
Referral and Consultation
Randomized Controlled Trials
Urine

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol : A randomized controlled study. / Gallagher, John Christopher G.; Goldgar, D.

In: Annals of Internal Medicine, Vol. 113, No. 9, 01.11.1990, p. 649-655.

Research output: Contribution to journalArticle

@article{a9fe31de4ffd4d378a7db5854997d64e,
title = "Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol: A randomized controlled study",
abstract = "Objective: To study the efficacy of synthetic 1,25 dihydroxyvitamin D3 (calcitriol) in the treatment of osteoporosis. Design: Two-year, double-blind, randomized clinical trial. Setting: University medical center. Patients: Fifty postmenopausal women with vertebral fractures recruited by referral. Intervention: Calcium intake was adjusted to 25 mmol/d (1000 mg/d) at baseline. Patients were then randomized to treatment with either calcitriol or placebo. During the study, calcium intake was reduced to 15 mmol/d (600 mg/d) and the dose of calcitriol was adjusted to maintain serum calcium <2.74 mmol/L (<11.0 mg/ dL) or urine calcium <9.96 mmol/d (<400 mg/d). Measurements and Main Results: After 2 years, the mean dose of calcitriol in the treated group was 0.62 μg/d. Bone mineral density of the spine increased 1.94{\%} with calcitriol therapy and decreased 3.92{\%} with placebo (P = 0.001). Total body calcium increased 0.21{\%} with calcitriol therapy and decreased 1.85{\%} with placebo (P = 0.004). Patients receiving placebo had significant decreases in spine density (P = 0.0007) and total body calcium (P = 0.0004). There were no differences in vertebral fracture rates between the groups. Renal function studies were not statistically different between the groups after 2 years. The treatment of postmenopausal osteoporotic women with synthetic calcitriol for 2 years was associated with increases in spine density and total body calcium. No adverse effects on renal function were seen after long-term calcitriol therapy.",
author = "Gallagher, {John Christopher G.} and D. Goldgar",
year = "1990",
month = "11",
day = "1",
language = "English",
volume = "113",
pages = "649--655",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "9",

}

TY - JOUR

T1 - Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol

T2 - A randomized controlled study

AU - Gallagher, John Christopher G.

AU - Goldgar, D.

PY - 1990/11/1

Y1 - 1990/11/1

N2 - Objective: To study the efficacy of synthetic 1,25 dihydroxyvitamin D3 (calcitriol) in the treatment of osteoporosis. Design: Two-year, double-blind, randomized clinical trial. Setting: University medical center. Patients: Fifty postmenopausal women with vertebral fractures recruited by referral. Intervention: Calcium intake was adjusted to 25 mmol/d (1000 mg/d) at baseline. Patients were then randomized to treatment with either calcitriol or placebo. During the study, calcium intake was reduced to 15 mmol/d (600 mg/d) and the dose of calcitriol was adjusted to maintain serum calcium <2.74 mmol/L (<11.0 mg/ dL) or urine calcium <9.96 mmol/d (<400 mg/d). Measurements and Main Results: After 2 years, the mean dose of calcitriol in the treated group was 0.62 μg/d. Bone mineral density of the spine increased 1.94% with calcitriol therapy and decreased 3.92% with placebo (P = 0.001). Total body calcium increased 0.21% with calcitriol therapy and decreased 1.85% with placebo (P = 0.004). Patients receiving placebo had significant decreases in spine density (P = 0.0007) and total body calcium (P = 0.0004). There were no differences in vertebral fracture rates between the groups. Renal function studies were not statistically different between the groups after 2 years. The treatment of postmenopausal osteoporotic women with synthetic calcitriol for 2 years was associated with increases in spine density and total body calcium. No adverse effects on renal function were seen after long-term calcitriol therapy.

AB - Objective: To study the efficacy of synthetic 1,25 dihydroxyvitamin D3 (calcitriol) in the treatment of osteoporosis. Design: Two-year, double-blind, randomized clinical trial. Setting: University medical center. Patients: Fifty postmenopausal women with vertebral fractures recruited by referral. Intervention: Calcium intake was adjusted to 25 mmol/d (1000 mg/d) at baseline. Patients were then randomized to treatment with either calcitriol or placebo. During the study, calcium intake was reduced to 15 mmol/d (600 mg/d) and the dose of calcitriol was adjusted to maintain serum calcium <2.74 mmol/L (<11.0 mg/ dL) or urine calcium <9.96 mmol/d (<400 mg/d). Measurements and Main Results: After 2 years, the mean dose of calcitriol in the treated group was 0.62 μg/d. Bone mineral density of the spine increased 1.94% with calcitriol therapy and decreased 3.92% with placebo (P = 0.001). Total body calcium increased 0.21% with calcitriol therapy and decreased 1.85% with placebo (P = 0.004). Patients receiving placebo had significant decreases in spine density (P = 0.0007) and total body calcium (P = 0.0004). There were no differences in vertebral fracture rates between the groups. Renal function studies were not statistically different between the groups after 2 years. The treatment of postmenopausal osteoporotic women with synthetic calcitriol for 2 years was associated with increases in spine density and total body calcium. No adverse effects on renal function were seen after long-term calcitriol therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025052617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025052617&partnerID=8YFLogxK

M3 - Article

VL - 113

SP - 649

EP - 655

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 9

ER -